Treatment Center Find the nearest therapy center The Oncidium foundation endeavors to make Radiotheranostics available for as many people as possible. Find the nearest therapy center and contact person thanks to the worldwide map of facilities providing Radiotheranostics-based treatments Find a center Make a Donation The generosity of donors allows the Oncidium foundation to support the development of new Radiotheranostics cancer treatments as well as to advance their accessibility worldwide.
For this reason, a Fund has been opened at the King Baudouin Foundation.

Make a donation and put your action at the heart of the fight against cancer.
DONATE
Treatment Center Register your therapy center Make sure that your center is linked to our website and define one or more direct expert(s) from your center that can become the entrance point for patients. Register now Be an Ambassador Become an Oncidium Ambassador The Oncidium foundation cannot act alone to be efficient and accelerate global access to Radiotheranostics for cancer treatments. The solution is to build a worldwide network of Ambassadors in each country for awareness and education campaigns, local collaborations, and shared knowledge. We need you! Get involved Oncidium Home Page access icon access, education, hope The Oncidium foundation focuses on raising awareness about Radiotheranostics as alternatives for cancer therapy and providing support to accelerate global access. education icon hope ribbon Oncidium Team Who we are The Oncidium foundation team is fully dedicated to promoting the developments or nuclear medicine therapy. To this day, many patients and non-nuclear practitioners are still unaware of the existence and benefits of Radiotheranostics for cancer treatments.

NEWS

  • FDA for Lu 177-PSMA-617 for mCRPC therapy

FDA for Lu-177-PSMA-617 for mCRPC treatment

Targeted Oncology, Sarah Karlovitch, June 17, 2021 

The FDA has granted breakthrough therapy designation to 177Lu-PSMA-617, […]

EVENTS

SIGN UP FOR OUR NEWSLETTER

CONNECT WITH US

2 days ago
The #FDA has granted breakthrough therapy designation to 177Lu-PSMA-617, an investigational #radioligandtherapy for the treatment of metastatic castration-resistant #prostatecancer (mCRPC)
https://t.co/bREULjxm0a
3 days ago
Key slide by @CSIntellPEG showing the anticipated impact of #theranostics. The field is "here to stay" with many new #isotopes, new entities & technologies. Access, costs and readiness are the objectives to reach for effective use of these technologies, globally.
#cancercare https://t.co/emZhpzZ7gF

ABOUT US

What we do…

Participate fully to the life of the foundation by volunteering. Everyone is welcome to contribute to help spread the word on this life saving technology. Explore the website, spread the link, tell others about the technology, come back with questions or with answers, or become an Ambassador for the Oncidium foundation in your country.

More about us >
Download brochure >

OUR SPONSORS AND SUPPORTERS

TELIX
Chrysalium Consulting
MEDraysintell
Nuclear Medicine Europe
edp sciences
Global Morpho Pharma
Warmth
LemerPax
sck cen
IBA
SNMMI